接受Janus激酶抑制剂治疗的类风湿关节炎患者中带状疱疹亚单位疫苗的血清学免疫原性与安全性
在瑞典Skåne大学医院纳入82例接受JAK抑制剂治疗的RA患者和51名健康对照,两组均接种两剂带状疱疹亚单位疫苗(Shingrix)。接种后两组疫苗特异性抗体水平均显著升高,患者接种后抗体水平低于对照,JAK抑制剂联合甲氨蝶呤者低于JAK抑制剂单药者;不良事件多为轻中度,1例患者发生带状疱疹,6例(6.5%)患者RA疾病活动度升高。
要点
- 接种后患者与对照疫苗特异性抗体水平均显著升高(P < 0.0001)。
- 80.5%患者和98.0%对照达到抗体水平≥4倍升高。
- 患者接种后抗体水平低于对照[比值0.44(95% CI 0.31, 0.63)]。
核心结论
- 带状疱疹亚单位疫苗在接受JAK抑制剂治疗的大多数RA患者中具有血清学免疫原性,且安全性可接受,这些结果支持在该脆弱人群中推荐使用该疫苗。
研究设计与样本
- 研究纳入瑞典Skåne大学医院风湿科接受JAK抑制剂治疗的RA患者(n = 82)和健康对照(n = 51),两组均接种两剂带状疱疹亚单位疫苗(Shingrix)。
- 采用间接ELISA分析疫苗特异性抗体应答,采用协方差分析比较患者与对照接种后抗体水平,采用多变量线性回归分析疫苗应答的潜在预测因素。
- 分析自我报告的不良事件和RA疾病活动度变化。
主要发现
- 接种后,患者和对照的疫苗特异性抗体水平均显著升高(P < 0.0001)。
- 80.5%的患者和98.0%的对照达到抗体水平≥4倍升高。
- 患者接种后抗体水平低于对照[比值0.44(95% CI 0.31, 0.63)]。
- 接受JAK抑制剂联合甲氨蝶呤治疗的患者接种后抗体水平低于JAK抑制剂单药治疗患者[比值0.43(95% CI 0.24, 0.79)]。
- 不良事件常见,多为轻中度;1例患者发生带状疱疹,6例患者(6.5%)接种后RA疾病活动度升高。
临床怎么用
- 作者认为这些结果支持在该脆弱人群中推荐使用带状疱疹亚单位疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients with RA treated with Janus kinase inhibitors (JAKis) are at increased risk of herpes zoster (HZ). The objective of this study was to investigate the serological immunogenicity and safety of the HZ subunit (HZ/su) vaccine in RA patients treated with JAKi, for which little is known. METHODS: RA patients treated with JAKi (n = 82) at the Department of Rheumatology, Skåne University Hospital, Lund and Malmö, Sweden, and healthy controls (n = 51) received two doses of the HZ/su vaccine (Shingrix). Vaccine-specific antibody responses were analysed using indirect ELISA. Post-vaccination antibody levels were compared between patients and controls using analysis of covariance. Potential predictors for vaccine response were investigated using a multivariable linear regression analysis. Self-reported adverse events (AEs) and changes in RA disease activity were analysed. RESULTS: Following vaccination, vaccine-specific antibody levels increased significantly in both patients and controls (P < 0.0001). A total of 80.5% of patients and 98.0% of controls achieved a ≥4-fold increase in antibody levels. Post-vaccination antibody levels were lower in patients than controls [ratio 0.44 (95% CI 0.31, 0.63)] and lower in patients receiving JAKi + methotrexate than JAKi monotherapy [ratio 0.43 (95% CI 0.24, 0.79)]. AEs, mostly mild/moderate, were common. One patient developed HZ and six patients (6.5%) had increased RA disease activity following vaccination. CONCLUSION: The HZ/su vaccine was serologically immunogenic in most RA patients treated with JAKi. Moreover, the vaccine had an acceptable safety profile. These results support recommendations for use of the HZ/su vaccine in this vulnerable population. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT03886038.
引用
- Källmark H, Bergström T, Nagel J, et al. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors. Rheumatology (Oxford). 2024. PMID: 37851412. doi:10.1093/rheumatology/kead552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。